Beyond Cancer Announces Approval by the Israeli Ministry of Health to Conduct a Phase 1b Clinical Trial Utilizing Low Volume Ultra-High Concentration Nitric Oxide (LV UNO) in Combination with Anti-PD-1 Therapy
December 03, 2024 16:05 ET | Source: Beyond Air™ The Phase 1b…
Bharath Advanced Therapeutics (BAT) advancing Cancer treatment in India by setting new benchmarks in affordable and transformational care
HYDERABAD, India, Dec. 3, 2024 /PRNewswire/ -- Bharath Advanced Therapeutics (BAT), as…
Bharath Advanced Therapeutics (BAT) and FABA Present Cancer NEXT 2024: Pioneering Innovation in Cancer Research
HYDERABAD, India, Nov. 29, 2024 /PRNewswire/ -- Bharath Advanced Therapeutics (BAT) and…
Bharath Advanced Therapeutics (BAT) and FABA Present Cancer NEXT 2024: Pioneering Innovation in Cancer Research
HYDERABAD, India, Nov. 29, 2024 /PRNewswire/ -- Bharath Advanced Therapeutics (BAT) and…
Bharath Advanced Therapeutics (BAT) and FABA Present Cancer NEXT 2024: Pioneering Innovation in Cancer Research
HYDERABAD, India, Nov. 29, 2024 /PRNewswire/ -- Bharath Advanced Therapeutics (BAT) and…
Bharath Advanced Therapeutics (BAT) and FABA Present Cancer NEXT 2024: Pioneering Innovation in Cancer Research
HYDERABAD, India, Nov. 29, 2024 /PRNewswire/ -- Bharath Advanced Therapeutics (BAT) and…
Menarini Group Presents New and Expanded Data at the 2024 San Antonio Breast Cancer Symposium Reinforcing the Role of ORSERDU (Elacestrant) for Patients with ER+, HER2- Advanced or Metastatic Breast Cancer (mBC)
Real-world evidence bolsters the efficacy of ORSERDU for the treatment of patients…
Menarini Group Presents New and Expanded Data at the 2024 San Antonio Breast Cancer Symposium Reinforcing the Role of ORSERDU (Elacestrant) for Patients with ER+, HER2- Advanced or Metastatic Breast Cancer (mBC)
Real-world evidence bolsters the efficacy of ORSERDU for the treatment of patients…
Menarini Group Presents New and Expanded Data at the 2024 San Antonio Breast Cancer Symposium Reinforcing the Role of ORSERDU (Elacestrant) for Patients with ER+, HER2- Advanced or Metastatic Breast Cancer (mBC)
Real-world evidence bolsters the efficacy of ORSERDU for the treatment of patients…
Anocca Announces Submission of Clinical Trial Application for Multi-asset Trial VIDAR-1 in Advanced Pancreatic Cancer
November 26, 2024 03:00 ET | Source: Anocca AB Application to the…